Information Provided By: 
Fly News Breaks for February 10, 2020
DGX
Feb 10, 2020 | 06:48 EDT
Mizuho analyst Ann Hynes raised her price target for Quest Diagnostics to $122 from $116 and keeps a Buy rating on the shares after hosting investor meetings with management. The company remains excited about the potential to gain market share given its increased in-network access to commercial lives, Hynes tells investors in a research note. The analyst expects Quest to be a market share gainer over the next few years.
News For DGX From the Last 2 Days
There are no results for your query DGX
